Aquestive Therapeutics, Inc.
AQST-108
androgenic alopecia
Resolved
7days ago
Phase 1 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 1 trial results for AQST-108 in androgenic alopecia are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“the data readout from the study is expected in the second quarter of 2026.”